Antidote Strengthens Clinical Trial Enrollment Collaboration
SEQSTER and Antidote have revolutionized patient matching and clinical research efficiency. SEQSTER’s patient-centric healthcare platform provides a comprehensive view...
Jon Napitupulu
Genentech Unveils Second Chance for Susvimo to Combat AMD
The Food and Drug Administration (FDA) has approved updates to Susvimo, an eye implant treatment for wet age-related macular...
Genexine and EPD Bio Announce Merger, Paving the Way for Revolutionized Drug Development
Genexine, a Korean biopharmaceutical company, has merged with EPD Biotherapeutics, specializing in targeted protein degradation (TPD) technology. This merger...
Announcing Calidi’s Stock Split
Calidi Biotherapeutics has authorized a one-for-ten reverse stock split, effective July 15, 2024. The split will be applied to...
Acticor Biotech: Disclosure of Voting Rights, Shares May 2024
ACTICOR BIOTECH, a clinical-stage pharmaceutical company, reports its voting rights and shares as of May 31, 2024. The company...
Merck and Orion Exclusive Rights to Opevesostat for Metastatic Prostate Cancer
Merck and Orion Corporation have converted their co-development and co-commercialization agreement for opevesostat into an exclusive global license for...
How N-Power Medicine’s Series B Funding Will Revolutionize Oncology Trial Access
N-Power Medicine has secured initial funding in a Series B round, boosting its total funding to $72 million. Led...
TAURx Submits Extraordinary Application for HMTM as Alzheimer’s Disease Breakthrough
TauRx Pharmaceuticals has submitted a Marketing Authorisation Application (MAA) in the UK for hydromethylthionine mesylate (HMTM), a potential treatment...
Mendel’s AI System Outperforms GPT-4 in Patient Cohort Identification
Mendel, a leader in clinical AI, has announced advancements in its neuro-Symbolic AI system, which automates the identification of...
Breakthrough Med: Epcoritamab Revolutionizes Follicular Lymphoma Treatment
The European Medicines Agency (EMA) has recommended granting marketing authorization for epcoritamab, a monoclonal antibody for treating relapsed or...